DBV Technologies (NASDAQ:DBVT) Sees Large Volume Increase – Here’s Why

Shares of DBV Technologies S.A. (NASDAQ:DBVT) saw unusually-strong trading volume on Wednesday . Approximately 626,482 shares were traded during trading, an increase of 118% from the previous session’s volume of 287,370 shares.The stock last traded at $18.56 and had previously closed at $18.16.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on DBVT shares. Citigroup reaffirmed an “outperform” rating on shares of DBV Technologies in a report on Friday, May 1st. Wall Street Zen raised DBV Technologies from a “sell” rating to a “hold” rating in a report on Saturday, May 2nd. Citizens Jmp increased their price target on DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a report on Friday, May 1st. Finally, Guggenheim reissued a “buy” rating and set a $51.00 price target on shares of DBV Technologies in a report on Monday, May 4th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $40.25.

DBV Technologies Stock Up 3.1%

The business has a fifty day simple moving average of $20.05 and a two-hundred day simple moving average of $19.33. The company has a market cap of $1.11 billion, a P/E ratio of -4.18 and a beta of -0.96.

DBV Technologies (NASDAQ:DBVT) last posted its earnings results on Thursday, April 30th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.42). DBV Technologies had a negative net margin of 2,895.37% and a negative return on equity of 129.88%. The firm had revenue of $0.90 million during the quarter, compared to the consensus estimate of $1.11 million. On average, equities analysts predict that DBV Technologies S.A. will post -0.47 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Artisan Partners Limited Partnership raised its stake in shares of DBV Technologies by 6,273.4% in the fourth quarter. Artisan Partners Limited Partnership now owns 3,309,055 shares of the company’s stock worth $63,435,000 after buying an additional 3,257,135 shares during the period. Vivo Capital LLC raised its stake in shares of DBV Technologies by 8.4% in the first quarter. Vivo Capital LLC now owns 2,667,569 shares of the company’s stock worth $55,726,000 after buying an additional 205,943 shares during the period. Siren L.L.C. bought a new position in shares of DBV Technologies in the fourth quarter worth about $35,606,000. Adage Capital Partners GP L.L.C. bought a new position in shares of DBV Technologies in the second quarter worth about $9,659,000. Finally, MPM Bioimpact LLC bought a new position in shares of DBV Technologies in the second quarter worth about $9,649,000. Institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.